These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1812425)

  • 41. Class 1/3 outer membrane protein vaccine against group B, type 15, subtype 16 meningococci.
    Poolman JT; Beuvery EC; Hopman CT; Witvliet MH; Timmermans HA; Teerlink T; Zanen HC
    Dev Biol Stand; 1986; 63():147-52. PubMed ID: 3091433
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
    Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
    Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Meningococcal disease in São Paulo, Brazil.
    Costa W; Sacchi CT; Ramos S; Milagres L; Prigenzi LS
    NIPH Ann; 1991 Dec; 14(2):215-6; discussion 216-8, 222-4. PubMed ID: 1812434
    [No Abstract]   [Full Text] [Related]  

  • 44. Serologic correlates of protection for evaluating the response to meningococcal vaccines.
    Balmer P; Borrow R
    Expert Rev Vaccines; 2004 Feb; 3(1):77-87. PubMed ID: 14761245
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
    Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Meningococcal disease: a review on available vaccines and vaccines in development.
    Bröker M; Fantoni S
    Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Second generation meningococcal OMP-LPS vaccines.
    Poolman JT; van der Ley PA; Wiertz EJ; Hoogerhout P
    NIPH Ann; 1991 Dec; 14(2):233-41. PubMed ID: 1725922
    [No Abstract]   [Full Text] [Related]  

  • 48. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland.
    Perkins BA; Jonsdottir K; Briem H; Griffiths E; Plikaytis BD; Hoiby EA; Rosenqvist E; Holst J; Nokleby H; Sotolongo F; Sierra G; Campa HC; Carlone GM; Williams D; Dykes J; Kapczynski D; Tikhomirov E; Wenger JD; Broome CV
    J Infect Dis; 1998 Mar; 177(3):683-91. PubMed ID: 9498448
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Meningococcal Serogroup B Vaccine Protection Trial in Norway 1988-91. Proceedings of the report meeting. Oslo, September 12-13, 1991.
    NIPH Ann; 1991 Dec; 14(2):46-251. PubMed ID: 1687482
    [No Abstract]   [Full Text] [Related]  

  • 50. [The molecular parameters of a meningococcal serogroup B protein-polysaccharide vaccine].
    Bobyleva GV; Artiukhova II; Kuvakina VI; Basnak'ian IA
    Zh Mikrobiol Epidemiol Immunobiol; 1996; (5):39-43. PubMed ID: 9082727
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Immunologic behavior of meningococcal vaccines].
    Requejo HI
    Rev Saude Publica; 1997 Aug; 31(4):402-16. PubMed ID: 9595770
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gram-negative outer membrane vesicles in vaccine development.
    Collins BS
    Discov Med; 2011 Jul; 12(62):7-15. PubMed ID: 21794204
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanisms of defense formation against meningococcal infection in mice immunized with synthetic peptides.
    Chibiskova OV; Kotel'nikova OV; Nesmeyanov VA; Alliluev AP; Vol'pina OM; Koroev DO; Filatova MP
    Bull Exp Biol Med; 2007 Jun; 143(6):720-2. PubMed ID: 18239810
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Meningococcal vaccine trial in Norway.
    Fine PE
    Lancet; 1991 Dec; 338(8780):1456-7. PubMed ID: 1683438
    [No Abstract]   [Full Text] [Related]  

  • 55. Meningococcal disease in healthcare workers. Vaccine is available in Latin America.
    Trujillo C
    BMJ; 2000 Jan; 320(7229):247; author reply 248-9. PubMed ID: 10642243
    [No Abstract]   [Full Text] [Related]  

  • 56. Group A meningococcal polysaccharide vaccine and course of the group A meningococcal epidemic in Finland.
    Peltola H
    Scand J Infect Dis; 1978; 10(1):41-4. PubMed ID: 635475
    [TBL] [Abstract][Full Text] [Related]  

  • 57. "Herd immunity" and the meningococcal vaccine trial in Norway.
    Bjune G
    Lancet; 1992 Aug; 340(8814):315. PubMed ID: 1353236
    [No Abstract]   [Full Text] [Related]  

  • 58. Letter: Serogroup C meningococcal vaccine: limited-use license by FDA.
    Frothingham TE
    JAMA; 1974 Sep; 229(10):1287. PubMed ID: 4408283
    [No Abstract]   [Full Text] [Related]  

  • 59. New therapies and vaccines for meningococcal disease.
    Carrol ED; Thomson AP; Hart CA
    Expert Opin Investig Drugs; 2001 Aug; 10(8):1487-500. PubMed ID: 11772264
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Meningococcal disease requires an 'out of hours' public health response.
    Riordan FA; Thompson AP
    Commun Dis Public Health; 2000 Mar; 3(1):68-9. PubMed ID: 10743327
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.